89bio, Inc. (ETNB)
Market Cap | 1.14B |
Revenue (ttm) | n/a |
Net Income (ttm) | -118.64M |
Shares Out | 75.48M |
EPS (ttm) | -1.93 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,132,720 |
Open | 15.72 |
Previous Close | 15.68 |
Day's Range | 15.00 - 15.91 |
52-Week Range | 5.24 - 22.93 |
Beta | 0.72 |
Analysts | Strong Buy |
Price Target | 38.75 (+156.79%) |
Earnings Date | Nov 9, 2023 |
About ETNB
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for ETNB stock is "Strong Buy." The 12-month stock price forecast is $38.75, which is an increase of 156.79% from the latest price.
News

89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)
–Supported by positive data in F2/F3 and F4 NASH patients from the ENLIVEN Phase 2b trial of pegozafermin– –Discussions with regulatory agencies regarding the NASH Phase 3 program planned for the four...

89bio to Participate in the 2023 Cantor Global Healthcare Conference
SAN FRANCISCO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for th...

89bio to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
SAN FRANCISCO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for th...

89bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
– Published data from ENLIVEN Phase 2b trial of pegozafermin in NASH in The New England Journal of Medicine; presented the data in a late-breaker session at the EASL International Liver Congress –

89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, July 12, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of i...

Weight-loss drugs in development aim to replace injections with pills
Wall Street's obsession with next-generation obesity and diabetes treatments intensified over the weekend as drugmakers presented new clinical-trial data on the drugs — including weight-loss pills in ...

89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine
– Published data showed consistent and significant reductions in triglycerides, atherogenic lipoproteins and liver fat, and pegozafermin's favorable safety and tolerability profile –

Data from 89bio's ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Liver Congress
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant changes on both primary histology endpoints –

89bio shares rise as analysts see improved outlook for NASH treatments
Shares of clinical-stage biopharma company 89bio Inc. ETNB, +4.38% gained 4.8% premarket on Tuesday as Evercore ISI analysts initiated coverage of the stock with an outperform rating. The company is f...

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, June 07, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of i...

89bio Announces Late-Breaker Oral Presentation of Data from the Phase 2 ENLIVEN Study of Pegozafermin at EASL International Liver Congress 2023
SAN FRANCISCO, June 07, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the...

89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)
SAN FRANCISCO, May 23, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the ...

89bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
– Positive topline results from ENLIVEN Phase 2b trial of pegozafermin in NASH demonstrated high statistical significance on both primary histology endpoints supporting advancement to Phase 3; discuss...

89bio to Participate in Upcoming Investor Conferences
SAN FRANCISCO, May 02, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the ...

89bio's public stock offering upsized by 38%, priced at a 4% discount
89bio Inc. ETNB, +23.83% said Friday that its public offering of stock, which the biopharmaceutical company launched after a 55% surge in its stock in the past two days, was upsized by about 38%. The ...

89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common Stock
SAN FRANCISCO, March 24, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therap...

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
SAN FRANCISCO, March 22, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therap...

89bio's stock rallies 48% on new NASH data
Shares of 89bio Inc. ETNB, -7.06% soared about 48% in premarket trading on Wednesday after the company said its experimental treatment for nonalcoholic steatohepatitis (NASH) led to NASH resolution co...

89bio's Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks
- 44mg Q2W dose had a placebo-adjusted effect size of 20% on at least one-stage fibrosis improvement without worsening of NASH (p=0.008) and 24% on NASH resolution without worsening of fibrosis (p=0.0...

89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
– Topline results from ENLIVEN Phase 2b NASH trial on track for first quarter of 2023 –

89bio Presents New Analysis of Data from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG regardless of their background lipid-modifying thera...

89bio to Present Additional Pegozafermin Data in Severe Hypertriglyceridemia from Phase 2 ENTRIGUE Study at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology
SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the...

89bio to Participate in the SVB Securities Global Biopharma Conference
SAN FRANCISCO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the...

89bio Provides Business Update and Outlook for 2023
– Topline results from ENLIVEN Phase 2b NASH trial on track for first quarter of 2023 –

89bio Announces Publication of Results of Phase 1b/2a Study of Pegozafermin for the Treatment of NASH in The Lancet Gastroenterology & Hepatology
– Data from cohorts 1-6 in the proof-of-concept study showed pegozafermin was generally well tolerated and had beneficial therapeutic effect in reducing liver fat and improving markers of liver injury...